Another Case Report on CRP apheresis in COVID-19 published.


Recently a new case report has been published in Frontiers in Immunology about the first COVID-19 patient at the onset of a severe COVID-19 course. Small heads-up: it turned out amazingly well!

New Case Report on a young COVID-19 patient published


Another case report has been published on the successful treatment of a young, ventilated COVID-19 patient in Immenstadt. One very effective CRP apheresis was sufficient. Afterwards, the patient's clinical parameters were back to normal.

Article about the CAMI-1 study published in "Intensiv-News"


In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.

Clinical trial CRP apheresis after myocardial infarction published


Results of the first clinical trial of CRP apheresis after acute myocardial infarction (CAMI1) were published in the cardiology journal Frontiers in Cardiovascular Medicine.
"CRP apheresis as anti-inflammatory therapy for acute myocardial infarction: results from the CAMI-1 trial."
The article describes that C-reactive protein substantially triggers myocardial damage after myocardial infarction.

Review on the pathomechanism of CRP published

"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.

Review on CRP apheresis published

In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).